✦ LIBER ✦

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

✍ Scribed by Terpos, E; Mihou, D; Szydlo, R; Tsimirika, K; Karkantaris, C; Politou, M; Voskaridou, E; Rahemtulla, A; Dimopoulos, M A; Zervas, K

Book ID: 110056412
Publisher: Nature Publishing Group
Year: 2005
Tongue: English
Weight: 230 KB
Volume: 19
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2403890

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The combination of bortezomib, melphalan

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

✍ Heath, D; Terpos, E; Kastritis, E; Roussou, M; Christoulas, D; Anagnostopoulos, 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 177 KB

The combination of bortezomib, melphalan

✍ Terpos, E; Kastritis, E; Roussou, M; Heath, D; Christoulas, D; Anagnostopoulos, 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 40 KB

The combination of intermediate doses of

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma

✍ E. Hatjiharissi; E. Terpos; M. Papaioannou; C. Hatjileontis; V. Kaloutsi; G. Gal 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

## Abstract The aim of the study was the evaluation of anti‐angiogenic activity of the combination of intermediate doses of thalidomide and dexamethasone in patients with refractory/relapsed myeloma. Twenty‐five patients were included in the study. Microvessel density (MVD) was evaluated in marrow